Phase II trial of vinblastine sulfate for metastatic urothelial tract tumors.

Abstract

Vinblastine sulfate 0.10-0.15 mg/kg IV every week, was given to 37 patients with bidimensionally measurable, metastatic transitional cell carcinoma of the urothelial tract. Twenty-eight patients, the majority of whom had received extensive prior chemotherapy, had an adequate trial and five (18%; 95% confidence limits, 3-33%) achieved a partial remission (greater than 50% decrease in tumor size) of 2-5 months' duration. Responding sites included lung and nodal metastases. Toxicity, primarily leukopenia, was mild to moderate. The 18% response rate obtained in heavily pretreated cases suggests that vinblastine sulfate has some efficacy in the treatment of patients with advanced urothelial tract tumors.

• Authors: M S Blumenreich, A Yagoda, R B Natale, R C Watson
• Journal: Cancer (Cancer) Vol. 50 Issue 3 Pg. 435-8 (Aug 01 1982) ISSN: 0008-543X [Print] United States
• PMID: 7093886 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Topics

• Adult
• Aged
• Carcinoma, Transitional Cell (drug therapy)
• Drug Administration Schedule
• Drug Evaluation
• Female
• Humans
• Injections, Intravenous
• Male
• Middle Aged
• Neoplasm Metastasis
• Urinary Bladder Neoplasms (drug therapy)
• Urologic Neoplasms (drug therapy)